Boucherville, QC, June 28, 2016 – Sandoz Canada announced today that Health Canada has accepted for review its regulatory submission for a subsequent entry biologic version (also known as biosimilar) of etanercept, a tumor necrosis factor alpha (TNF-alpha) inhibitor. Subsequent entry biologics are follow-on versions of original biological molecules and undergo their own confirmatory clinical safety and efficacy studies as the final part of a comprehensive comparability exercise.

Read More [2]